|
Fernandez-Sevilla LM, Valencia J, Ortiz-Sanchez P, Fraile-Ramos A, Zuluaga P, Jimenez E, Sacedon R, Martinez-Sanchez MV, Jazbec J, Debeljak M, Fedders B, Stanulla M, Schewe D, Cario G, Minguela A, Ramirez M, Varas A, Vicente A. High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcomes. Blood. 2022 Jun 2;139(22):3303-3313. doi: 10.1182/blood.2021013506. PubMed PMID: 35313334; PubMed Central PMCID: PMC11022983.
AÑO: 2022; IF: 20.3
|
35313334
|
Ramos Elbal E, Fuster JL, Campillo JA, Galera AM, Cortes MB, Llinares ME, Jimenez I, Plaza M, Banaclocha HM, Galian JA, Blanquer Blanquer M, Martinez Sanchez MV, Muro M, Minguela A. Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia. Clin Transl Oncol. 2023 Jan 4. doi: 10.1007/s12094-022-03042-z. Online ahead of print. PubMed PMID: 36598635.
AÑO: 2023; IF: 2.8
|
|
Ramos Elbal E, Fuster JL, Campillo JA, Galera AM, Cortes MB, Llinares ME, Jimenez I, Plaza M, Martinez Banaclocha H, Galian JA, Blanquer Blanquer M, Martinez Sanchez MV, Muro M, Minguela A. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia. Clin Transl Oncol. 2023 Jun 27. doi: 10.1007/s12094-023-03251-0. Online ahead of print. PubMed PMID: 37368200.
AÑO: 2023; IF: 2.8
|